Notice ID: 57e0e2e32c8b43e7ac61952adb35c4fcCombined Synopsis/Solicitation
Adult Vaccines 2024
Archived on April 20, 2024. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 4:00 PM UTC−04:00
- Posted
- March 29, 2024
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION
Notice details
- Office
- CDC OFFICE OF ACQUISITION SERVICES
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75D301-24-R-72943
- Notice ID
- 57e0e2e32c8b43e7ac61952adb35c4fc
Description
UPDATE 3/29/2024: The answers to vendor questions have been uploaded to this posting. The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) requires the award of one or more indefinite-delivery, indefinite-quantity contracts for the purchase of the following adult vaccines, at the estimated quantities listed, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration. See attached RFP for details. Hepatitis A Adult Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 1,000,000 doses Minimum: 100 doses Hepatitis B Adult Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 750,000 doses Minimum: 100 doses Hepatitis A & B Combination Adult Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $1.50 per dose Maximum: 250,000 doses Minimum: 100 doses Herpes Zoster Adult Vaccine: Min. Shelf Life 12 months Fed. Excise Tax N/A Maximum: 500,000 doses Minimum: 100 doses Human Papillomavirus (HPV9) Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 300,000 doses Minimum: 100 doses E-IPV Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 500,000 doses Minimum: 100 doses Measles, Mumps, and Rubella Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $2.25 per dose Maximum: 250,000 doses Minimum: 100 doses Meningococcal Conjugate-Serogroup B Meningococcal Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $1.50 per dose Maximum: 200,000 doses Minimum: 100 doses Mpox Vaccine: Min. Shelf Life 12 months Fed. Excise Tax TBD Maximum: 500,000 doses Minimum: 100 doses Serogroup B Meningococcal Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 200,000 doses Minimum: 100 doses Meningococcal Conjugate (Groups A, C, Y & W) Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 200,000 doses Minimum: 100 doses Pneumococcal Conjugate (PCV) Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 500,000 doses Minimum: 100 doses Pneumococcal Polysaccharide Vaccine: Min. Shelf Life 12 months Fed. Excise Tax N/A Maximum: 500,000 doses Minimum: 100 doses Tetanus and Diptheria Toxoids Vaccine for Adults: Min. Shelf Life 12 months Fed. Excise Tax $1.50 per dose Maximum: 100,000 doses Minimum: 100 doses Tetanus, Reduced Diptheria Toxoid & Acellular Pertusis (TdaP) Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $2.25 per dose Maximum: 850,000 doses Minimum: 100 doses Varicella Vaccine: Min. Shelf Life 12 months Fed. Excise Tax $0.75 per dose Maximum: 150,000 doses Minimum: 10 doses
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75D301-24-R-72943- Combined Synopsis
- 2×Combined SynopsisCurrentMar 25, 2024
Adult Vaccines 2024
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Emergency Pharmacy Order of DigiFAB | - | Sole Source / J&A | Open |
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | - | Pre-Solicitation | 11/11/2026 |
Central Alabama Veterans Healthcare System Radiopharmaceuticals | - | Special Notice | 09/15/2026 |
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information. | - | Solicitation | 02/15/2026 |
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79727R0010 for an unrestricted procurement for Nitroglycerin Patches, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DoD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere over the successful offeror/contractor's label. This product does not require unit of use packaging, as identified in the Schedule of Supplies. Patches must be boxed and must contain the bar code. The outside box as well as the patch must be barcoded. Solicitation #36E79727R0010 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about December 1, 2026, with a tentative closing date of December 15, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at SAM.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Jacob Werling. Questions can be e-mailed to Jacob.Werling@va.gov. The estimated annual requirements are as follows: REQUIREMENT DESCRIPTION ITEM DESCRIPTION UNIT of USE PKG. SIZE (Patches per Box) TOTAL EST. ANNUAL USAGE (Boxes) 1 Nitroglycerin 0.1 mg Patch N 30 4,982 2 Nitroglycerin 0.2 mg Patch N 30 10,044 3 Nitroglycerin 0.4 mg Patch N 30 8,720 4 Nitroglycerin 0.6 mg Patch N 30 2,213 | - | Pre-Solicitation | 11/18/2026 |
Additional Details
Solicitation Number
75D301-24-R-72943
Archive Date
Apr 20, 2024
Office Address
ATLANTA, GA, 30333